BioInvent International: BioInvent Selected to The Leukemia & Lymphoma Society's Therapy Acceleration Program and Receives $3 million Strategic Equity Investment

Strategic equity investment of USD 3 million to support clinical advancement of BI-1206 in Non-Hodgkin's LymphomaSupports also clinical development of BI-1808 in cutaneous T-cell lymphomaLLS TAP is a strategic

Related Keywords

Stockholm ,Sweden ,Martin Welschof ,Bioinvent Internationalview ,Cecilia Hofvander ,Instagram ,Twitter ,Leukemia Lymphoma Society ,Bioinvent International ,Bioinvent International Ab Nasdaq Stockholm ,Leukemia Lymphoma Society Therapy Acceleration Program ,Facebook ,Therapy Acceleration Program ,Nasdaq Stockholm ,Lymphoma Society ,Lore Gruenbaum ,Vice President ,Senior Director Investor ,Bioinvent ,Nternational ,Elected ,Leukemia ,Lymphoma ,Society ,Therapy ,Acceleration ,Program ,Eceives ,Billion ,Strategic ,Equity ,Investment ,